CNCE
Concert Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Market Cap: 521 Million
Primary Exchange: NASDAQ
Website: www.concertpharma.com
Shares Outstanding: 62.2 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1571 trading days
From: 2017-12-19 To: 2023-03-03
Lowest Point:
Concert Pharmaceuticals: Cheap Valuation With Multiple Programs Moving Forward
via: SeekingAlpha at 2019-06-13 09:46:22:000
Shares of Concert Pharmaceuticals ( CNCE ) have provided quite the roller coaster ride for investors. The stock was a winner for us the first time around , as it tripled after my original recommendation (due to a lucrative deal inked with Vertex Pharmaceuticals (VRTX)). Subsequent recommendat… read more...
Concert Pharma's CTP-692 shows favorable safety profile in early-stage studies
via: SeekingAlpha at 2019-06-12 04:12:37:000
Concert Pharmaceuticals (NASDAQ: CNCE ) announces that results from single-dose and multiple-ascending-dose Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of CTP-692 in healthy volunteers showed that it was well-tolerated across all dose ranges tested, including th… read more...
Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
via: Business Wire at 2019-06-12 03:00:00:000
The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|